ARCHIVES

Amgen Claimed QOL Benefit Despite FDA Label Change.

This article is from The Cancer Letter archive.

Vol. 33 No. 19 | May 18, 2007

Download PDF Visit The Full Archive

Related Articles

States Sue Bristol-Myers Alleging Firm Took Illegal Actions To Block Taxol Competitors

June 7, 2002

New Grant Program in Physical Activity

March 28, 2003

ORI Misconduct Findings Announced In Two Cases

July 12, 1996

Centers Eligible For Comprehensive Identification Names; Rauscher To Pick Four Now, Two More Later

May 24, 1974

Big Get Bigger, Litton Primate Contract Renewed

September 19, 1975

Revive Comprehensive Program, But Don’t Tie It to Grant Review, Center Executive Agrees

July 29, 1988